PTGX Protagonist Therapeutics Inc

By Chris Wack

Protagonist Therapeutics Inc. said Tuesday it saw positive topline results from its collaboration with Janssen Biotech Inc. in a Phase 2b clinical trial evaluating the oral Interleukin-23 receptor antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis.

The company said data from the 255-patient study showed that JNJ-2113 achieved the study's primary efficacy endpoint, with a statistically significant greater proportion of patients who received JNJ-2113 achieving a 75% improvement in skin lesions as measured by the Psoriasis Area and Severity Index at Week 16 in all five treatment groups.

A clear dose response was observed across an eight-fold dose range. Treatment was well tolerated, with no meaningful difference in frequency of adverse events across treatment groups versus placebo.

The Phase 2b trial was designed to assess the efficacy and safety of JNJ-2113 in patients with moderate-to-severe plaque psoriasis. It is a randomized study that evaluated three once-daily dosages and two twice-daily dosages of JNJ-2113 taken orally.

JNJ-2113 was discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Protagonist shares were up 19%, to $18.13, in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

March 07, 2023 08:37 ET (13:37 GMT)

Protagonist Therapeutics (NASDAQ:PTGX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Protagonist Therapeutics (NASDAQ:PTGX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024